NCT06030258 - IN10018 Combination Therapy in Treatment-naïve ES-SCLC | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

December 24, 2025

Study Completion Date

December 24, 2025

Conditions

Small Cell Lung Cancer Extensive Stage

Interventions

DRUG

IN10018

orally taken once daily

DRUG

Tislelizumab

200mg D1, Q3W, intravenously

DRUG

Carboplatin

AUC 5 mg/ml/min, D1, Q3W, intravenously

DRUG

Etoposide

Etoposide 100 mg/m2, D1-D3, Q3W, intravenously

Trial Locations (3)

RECRUITING

Shandong Province Cancer Hospital, Jinan

NOT_YET_RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

NOT_YET_RECRUITING

Henan Provincial People's Hospital, Zhengzhou

All Listed Sponsors

lead

InxMed (Shanghai) Co., Ltd.

INDUSTRY